This dual regulatory action ultimately effectively corrected PTZ-induced disorders of glutamate metabolism and epileptiform seizures by restoring the efficacy of extracellular glutamate clearance, revealing the translational potential of the AP-1/miR-155-5p/GLAST pathway as a novel target for epilepsy therapy (Gao et al., 2017). This evidence concerns the gene JUN and epilepsy.